1. Introduction {#s0005}
===============

As a disease most often diagnosed in late stages following vague abdominal symptoms, ovarian cancer remains the leading cause of gynecologic cancer death and 14,070 women were expected to die of ovarian cancer in 2018 ([@bb0070]). Up to 24% of women with ovarian cancer may harbor a deleterious germline mutation; the most common mutations are in the BRCA genes, but other genes are also associated with an increased risk of ovarian cancer including BRIP1, the Lynch associated genes, RAD51C, RAD51D, and STK11 ([@bb0055]). Interestingly, patients with invasive epithelial ovarian cancer and a germline BRCA1/2 mutation tend to have a better prognosis than sporadically occurring ovarian cancers ([@bb0005]).

Unlike breast cancer screening with mammograms and MRIs, the current ovarian cancer screening options of transvaginal ultrasound (TVUS) and Cancer Antigen 125 (Ca-125) have not proven effective in improving detection or survival in either the normal or high-risk population, as evidenced by the United Kingdom Trial of Ovarian Cancer Screening (UK-TOCS) and the United Kingdom Familial Ovarian Cancers Screening (UK-FOCS) trials ([@bb0065]; [@bb0025]). Thus, in order to improve outcomes, current recommendations to enable ovarian cancer mortality reduction should focus on prevention and risk reduction, both surgical with risk-reducing bilateral salpingo-oophorectomy (RRBSO) and medical with oral contraceptives. In hereditary breast and ovarian cancer (HBOC) patients, the National Comprehensive Cancer Network (NCCN) guidelines recommend RRBSO by 35--40 years of age for BRCA1 carriers and by 40--45 years of age for BRCA2 carriers, which is much earlier than the average age of menopause at 51 ([@bb0050]). For high-risk patients with a known BRCA mutation, this procedure has been shown to reduce the risk of ovarian cancer by up to 80%, breast cancer by 50%, and all-cause mortality by 77% ([@bb0015]). For high-risk patients without an identified genetic mutation, a thorough family history and risk stratification can be performed to estimate their cancer risks and clinical judgment can be used to guide screening and preventive measures.

However, RRBSO does come with both economic and physiologic costs, including early menopausal symptoms, impaired sexual function, metabolic syndrome, heart disease, bone density loss, and surgical complications such as wound infection, bowel obstruction, or bladder perforation ([@bb0045]). The University of Virginia Health System opened a High-Risk Breast and Ovarian Clinic in 2007 to provide personalized cancer risk stratification, genetic counseling/testing, cancer screening, and prevention options for high-risk patients. The objectives of this study were to determine surgical outcomes, complications, and subsequent cancer outcomes for high-risk women undergoing ovarian cancer risk-reducing surgery at an academic tertiary care institution.

2. Material and methods {#s0010}
=======================

Following Institutional Review Board (IRB) approval, a retrospective chart review identified women who underwent an ovarian cancer risk-reducing surgery at the University of Virginia and were followed in the High-Risk Breast/Ovarian Cancer clinic since 2007. Patients followed in this clinic were deemed to be at high risk after their initial consultation if they carried a known genetic mutation, or met clinical criteria for a potential hereditary cancer syndrome, or had a first or second degree relative with ovarian cancer, or met the high risk breast criteria (over 20--25% lifetime risk of breast cancer). Data were abstracted from the electronic medical record and included patient demographics, medical and reproductive history, family cancer history, mutation status, surgery performed, pathology results, prior pelvic ultrasound results, Ca-125 levels, and pre-/post-operative cancer diagnoses. The Clinical Data Repository was also utilized to obtain total costs of the procedures done. Statistical analysis was conducted using IBM SPSS Statistics 24 (Armonk, NY). Independent T tests were used for continuous variables, and Chi-Square tests were used for categorical variables.

3. Results {#s0015}
==========

One hundred and eighty-three high-risk women were identified with a mean age of 50.1 years and a mean BMI of 28.8 kg/m2 at the time of surgery ([Table 1](#t0005){ref-type="table"}). Age at time of surgery did not differ between women with and without identified mutations. Most women underwent screening with either Ca-125 and/or transvaginal ultrasound (TVUS) prior to their surgery. The majority (103; 56.2%) had strong family history of cancer consistent with a hereditary syndrome, or an ovarian cancer family history, or personal history of early breast/ovarian cancer without an identified mutation (14;7.7%). The remaining women carried a deleterious mutation in BRCA2 (33; 18.0%), BRCA1 (28; 15.3%), Lynch mutations (4; 2.2%) or p53 (1; 0.5%). The most common procedure performed was a RRBSO (89.1%) with or without a hysterectomy (32.8 and 56.2% respectively), followed by USO (4.4%), bilateral salpingectomy (4.9%) and hysterectomy/bilateral salpingectomy (1.6%). The vast majority of surgery (78%) was performed for risk reduction vs. 14.5% for symptoms and 7% due to abnormal screening. No ovarian or fallopian tube cancers were detected on screening. Mean surgical hospital costs, hospital charges, and physician charges were \$7637.17, \$24,691.52, and \$7592.98 respectively for the surgical procedures. There were no major surgical complications, readmissions, or mortalities.Table 1Demographics.Table 1CharacteristicKnown genetic mutation N (%) *N* = 66No known genetic mutation N (%) *N* = 117Total cohort N (%) *N* = 183Mean age entered HR clinic (years)48.3249.6749.18Mean age at procedure (years)49.0650.6850.1Race Caucasian57 (86.4)101 (86.3)159 (86.9) African American6 (9.1)11 (9.4)17 (9.3) Hispanic2 (3)2 (1.7)4 (2.2) Asian0 (0)2 (1.7)2 (1.1) American Indian1 (1.5)1 (0.9)2 (1.1)BMI (kg/m^2^)28.4329.1528.89Procedure Done BSO +/− hysterectomy[a](#tf0005){ref-type="table-fn"}65 (98.5)98 (83.8)163 (89.1) USO (one ovary remaining)1 (1.5)7 (6.0)8 (4.4) Hysterectomy only (2 ovaries remaining)03 (2.6)3 (1.6) Salpingectomy (2 ovaries remaining)09 (7.0)9 (4.9)Reason for Surgery Known deleterious mutation66--66 (35.9) Family cancer history--103104 (56.5) Personal history of breast cancer--1313 (7.1) Personal history of ovarian cancer--11 (0.5)Tube and Ovary Pathology Benign/no pathological abnormality62 (94)113 (96.6)175 (95.6) Atypia/malignancy4 (6.1)4 (3.4)8 (4.4)Procedure Costs (US Dollars) Hospital costs\$6907.03\$8081.32\$7637.17 Hospital charges\$23,283.70\$25,594.91\$24,691.52 Physician charges\$7605.97\$8117.02\$7592.98Cancer following procedure None56 (84.8)115 (98.3)171 (93.4) DCIS3 (4.5)1 (0.9)4 (2.2) Breast cancer6 (9.1)1 (0.9)7 (3.8) Primary peritoneal adenocarcinoma1 (1.5)01 (0.5)[^1]

All women underwent the Sectioning and Extensively Examining the Fimbriated End (SEE-FIM) protocol with extensive pathologic analysis which found two (1.1%) invasive ovarian cancers (one carcinosarcoma of ovary/tube, one granulosa cell), three (1.6%) serous tubal intraepithelial carcinomas (STIC), and one invasive fallopian tube cancer (0.5%). All tubal pathology was diagnosed in women with documented BRCA mutations. There were no statistically significant differences in age at procedure, Ca-125 levels, TVUS results, mutation status, or subsequent cancers between patients in which atypia or cancer was found on pathology compared to benign pathology ([Table 2](#t0010){ref-type="table"}). A clinical summary of the eight patients with abnormal pathology at the time of risk-reducing procedure can be found in [Table 3](#t0015){ref-type="table"}.Table 2Demographics with pathology outcomes (*N* = 184).Table 2FactorsCancer/Atypia *N* = 8Benign *N* = 175*P*-ValueAge at Surgery (years)52.649.980.445BMI (kg/m^2^)25.329.10.129Race0.932 Caucasian8150 African American017 Hispanic04 Asian02American Indian02CA-1250.627 Normal (≤30)6127 Elevated (\>30)05 Not performed243Mean CA-12515.1711.990.570Pelvic US0.663 Normal146 Abnormal -- benign369 Abnormal -- requires intervention1[a](#tf0010){ref-type="table-fn"}13 Not performed346Mutation Status0.404 Known deleterious mutation462 BRCA1226 BRCA2231 MSH202 MSH601 PMS201 P5301 No known mutation4113Cancer diagnoses following procedure0.592 None7164 Breast cancer16 DCIS04 Primary peritoneal serous adenocarcinoma01[^2]Table 3Abnormal pathology cases at RRBSO.Table 3CaseMutationProcedure doneAge at procedureRRBSO pathologyCancer before procedureCancer after procedure1NoneHyst/BSO42Ovary -- Adult granulosa cell tumorNoneNoneTubes -- NPA2NoneHyst/BSO43Ovary -- Hemorrhagic and follicle cystsNoneNoneTubes -- Epithelial Atypia3NoneHyst/BSO56Ovary -- Malignant muellerian mixed tumorNoneNoneTubes -- Malignant muellerian mixed tumor4NoneBSO66Ovary -- Leydig cell hyperplasia, rete ovariiBasal cell and squamous cell carcinoma of the skinNoneTubes -- Epithelial atypia & tubal endometriosis5BRCA1Hyst/BSO45Ovary -- Fibroma & cortical inclusion cystsNoneNoneTubes -- STIC6BRCA1Hyst/BSO59Ovary -- Serous cystadenoma with focal cytologic atypia & benign mesothelial-lined cystBreast CancerBreast CancerTubes -- NPA7BRCA2BSO44Ovary -- NPANoneNoneTubes -- STIC8BRCA2BSO66Ovary -- NPASquamous cell carcinoma of the tongueNoneTubes -- Stage I~A~ Fallopian Tube Cancer and STIC[^3]

Of the 175 patients with normal/benign pathology at the time of RRBSO, 12 patients were diagnosed with subsequent cancers (Breast-7, DCIS-4, Primary Peritoneal-1, [Table 4](#t0020){ref-type="table"}). Of note, the majority of women with subsequent cancers (7/12; 58.3%) carried BRCA 1 mutations, which represents 25% of the BRCA 1 mutation carriers within the cohort (7/28). The woman diagnosed with primary peritoneal cancer was 6 years out from her RRBSO (with benign RRBSO pathology and cytologic washings) and 9 years out from her prior breast cancer diagnosis. The peritoneal adenocarcinoma was discovered following a markedly elevated Ca-125 (606) and confirmed on laparoscopy with subsequent debulking and omentectomy/hysterectomy but with essentially only extensive miliary disease.Table 4Subsequent cancer diagnoses among women undergoing ovarian risk reducing surgery.Table 4CaseMutationProcedure doneAgePathology from RRBSOCancer before procedureCancer after procedure9NoneUSO + US47Ovary -- serous cystadenomaNoneDCISTubes -- NPA10NoneHyst/BSO62Ovary -- simple cystDCIS and endometrial cancerBreast cancerTube -- NPA11BRCA1BSO48Ovary -- NPABreast cancerPrimary peritoneal cancer 6 years laterTubes -- NPA12BRCA1BSO57Ovary -- endosalpingiosis and suture granulomaBreast cancer x2DCISTubes -- NPA13BRCA1BSO52NPANoneDCIS14BRCA1BSO58NPANoneBreast Cancer15BRCA1Hyst/BSO32Ovary -- NPABreast cancerBreast CancerTube -- fibrous adhesions16BRCA1BSO48Ovary -- "pelvic floater" calcified stromal tissueBreast cancerBreast CancerTube -- NPA17BRCA1Hyst/BSO59Ovary -- serous cystadenoma with focal cytologic atypiaBreast cancerBreast CancerTube -- NPA18BRCA2BSO55NPANoneDCIS19BRCA2BSO56Ovary -- follicle cystBreast cancerBreast CancerTube -- simple paratubal cyst20BRCA2BSO35Ovary -- simple cystBreast cancerBreast CancerTube -- simple paratubal cyst[^4]

4. Discussion {#s0020}
=============

Unfortunately, current ovarian cancer screening modalities with ultrasound and Ca-125 appear to be ineffective, perhaps influenced by the fact that the majority of serous epithelial cancers likely originate in the fallopian tubes ([@bb0060]). Cells from the fimbriae of fallopian tubes lie in close proximity to the ovaries, and cells may slough off and attach to the epithelial surface of the ovary. Presumed epithelial ovarian and fallopian tube cancers appear histologically identical and their clinical behavior is also indistinguishable. As RRBSO use has increased, it has been shown that up to 5.4% of asymptomatic BRCA1/2 carriers have occult carcinomas at the time of surgery and most occult cancers are found in the fallopian tube, similar to our study\'s findings ([@bb0075]). The presumed precursor lesion, known as a STIC, was incidentally found in three subjects, all of whom carried BRCA mutations for an overall STIC rate of 3/61 (4.9%) for BRCA mutation carriers and 0% for wildtype-BRCA patients.

A key to developing a more effective screening method is discovering the lead time to developing a STIC as well as the time from STIC development to an invasive cancer as those are the times when more targeted interventions could be implemented. The time from STIC to invasive cancer has been suggested to be approximately 7 years and has guided the recommendation for RRBSO at 35--40 years of age in BRCA1 patients ([@bb0030]). Our study included only one patient outcome to potentially support this timeline, the BRCA1 patient who developed primary peritoneal cancer 6 years after having a RRBSO (at a much later than recommended 48 years of age) with close sectioning and normal pathology. Presumably the fallopian tube epithelial cells were exfoliated or remained following the RRBSO procedure or the cancer developed de novo in the peritoneum. It has been suggested that including peritoneal washings at the time of RRBSO (done routinely as part of our practice) may aid in detection of abnormal cytology and guide staging for those found with early invasive or in-situ pathology, but this patient did have negative cytology at original RRBSO ([@bb0040]).

With ineffective current screening, removal of both ovaries and fallopian tubes remains the best method of reducing the risk of developing ovarian cancer in high-risk women. These procedures come with financial, physical, and psychological costs to the patient, primarily due to the premature loss of the ovarian hormones, perhaps explaining the later age at time of surgery within our cohort which had more high-risk women without a defined mutation. The average financial costs of RRBSO in our cohort, as expected, are lower than the average cost for ovarian cancer treatment, estimated by one institution to average \$211,940 per patient ([@bb0035]), and a pre-emptive surgery results in improved survival and decreased costs for patients and society.

Ongoing studies investigating the efficacy of salpingectomy (rather than RRSO) will hopefully help to answer the questions about the efficacy and safety of this intervention that could reduce the consequences of premature ovarian removal. This strategy of both opportunistic salpingectomy in normal risk women as well as staged salpingectomy followed by oophorectomy at a later time point to preserve hormonal function in high risk women is currently gaining traction and is under study. Two potential safety concerns for this strategy are that not all ovarian cancers arise in the fallopian tube and also, a recent study found that fimbrial tissue may actually remain on the ovaries following a salpingectomy in 16% of patients with unclear clinical significance ([@bb0020]). In our study, the one epithelial fallopian tube cancer was found in a BRCA carrier who was found to have the deleterious mutation at a very late (age 65) and thus her surgery was performed 20 years later than would be recommended for that population.

Nearly all of the women in our study had risk-reducing surgeries at an age much later than recommended, possibly due to personal risk/benefit analysis, insurance coverage of surgeries especially in women lacking a defined mutation, or lack of clarity about cancer risk and optimal timing. It is imperative that high-risk women are identified by their physicians and referred to specialized cancer or genetic specialist centers so as to have access to this lifesaving intervention, if appropriate. A recent study of a community OB/GYN practice demonstrated that 23.8% of women met NCCN criteria guidelines for genetic testing due to high risk of hereditary cancer ([@bb0010]). Warning signs prompting referral for further high-risk evaluation for potential ovarian cancer risk include personal or family history of cancers associated with genetic syndromes such ovarian cancer, breast cancer, pancreatic cancer, male breast cancer, and endometrial or colon cancer. Multiple family members are often affected and at an earlier age than most sporadic malignancies. Continuing to educate primary care physicians as well as practicing OB/GYN\'s to recognize these hereditary flags is imperative. Of note, the women followed in this study had surgeries prior to the stronger recommendation of hysterectomy in BRCA1 patients for endometrial cancer risk reduction, and most hysterectomies done in this study were simply based on patient/physician preference or other indications for a hysterectomy(e.g. fibroids).

Consideration of the effects of ovaries in the development of breast cancer in patients with BRCA mutations must also be taken into account. Of the BRCA1/2 patients in our study, 16.4% (10/61) developed subsequent related cancers (DCIS, breast, and peritoneal cancer), in contrast to 1.6% (2/122) of patients without a confirmed BRCA1/2 mutation. This is especially relevant for patients with BRCA2 mutations, in whom breast cancer is often estrogen receptor positive and thus susceptible to continued production of estrogen by remaining ovaries.

In conclusion, germline BRCA germline mutations impart greatly increased risk for the development of ovarian cancer, which is often derived from fallopian tube epithelium rather than purely the ovaries themselves. In order to truly decrease ovarian cancer mortality, there must be a renewed focus on identifying such high-risk patients to allow for the option of a RRBSO well prior to the potential onset of a likely fatal cancer.
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[^1]: 60 women underwent concomitant hysterectomy, the most common pathology was fibroids (34).

[^2]: Ultrasound abnormality was on opposite side of the microscopic atypia that was found.

[^3]: Hyst/BSO = hysterectomy and bilateral salpingo-ophorectomy; NPA = no pathologic abnormality; STIC = serous tubal intraepithelial cancer.

[^4]: BSO = bilateral salpingo-oophorectomy; Hyst = hysterectomy; DCIS = ductal carcinoma in situ (breast cancer precursor); NPA = no pathologic abnormality.
